Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Another TIGIT trial fails as BeiGene scraps Phase 3 drug
3 months ago
Novartis’ Chinook-originated kidney disease drug gets accelerated approval
3 months ago
Sarepta, Roche pause Elevidys trials in Europe following patient death
3 months ago
Edgewise's heart drug shows promise in Phase 2 trial
3 months ago
Axsome reports Phase 3 depression fail for Sunosi
3 months ago
Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed
3 months ago
Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial
3 months ago
Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15
3 months ago
Bioregnum
Special
RNA editing startup raises $155M to bring liver and lung disease therapy into clinic
3 months ago
Financing
Startups
Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia
3 months ago
Tenaya to lay off about one-third of staff, reveals heart gene therapy data
3 months ago
Cell/Gene Tx
Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street
3 months ago
Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer
3 months ago
Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy
3 months ago
Pharma
AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival
3 months ago
Marks’ exit at FDA rattles an already teetering biotech industry
3 months ago
FDA+
Lilly's heart disease drug could be dosed as little as once a year, study shows
3 months ago
Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class
3 months ago
BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study
3 months ago
Vertex’s second-generation diabetes cell therapy fails early-stage study
3 months ago
Cell/Gene Tx
‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic
3 months ago
In Focus
Lykos’ interim CEO is set to step down
3 months ago
Pharma
Bluebird gets new M&A bid, seeking to top private equity offer
3 months ago
Deals
At long last, Novartis’ radiopharma drug Pluvicto gets an expanded label
3 months ago
FDA+
First page
Previous page
8
9
10
11
12
13
14
Next page
Last page